Monica L Guzman-Limon1, Shuai Jiang2, Derek Ng2, Joseph T Flynn3, Bradley Warady4, Susan L Furth5, Joshua A Samuels1. 1. McGovern Medical School at UTHealth, Pediatric Nephrology & Hypertension, Houston, TX (M.L.G.-L., J.A.S.). 2. Johns Hopkins University, Baltimore, MD (S.J., D.N.). 3. Department of Pediatrics, University of Washington, and Division of Nephrology, Seattle Children's Hospital, WA (J.T.F.). 4. The Children's Mercy Hospital, Kansas City, MO (B.W.). 5. The Children's Hospital of Philadelphia, PA (S.L.F.).
Abstract
BACKGROUND: Nocturnal hypertension is a risk factor for chronic kidney disease (CKD) progression among adults. In children, effects of nocturnal hypertension on CKD progression is less studied. METHODS: We investigated the relationships between nocturnal, daytime, or sustained hypertension and progression to kidney replacement therapy in children using Cox proportional hazards models. Nocturnal and diurnal hypertension respectively defined as: mean blood pressure >95th percentile and/or load >25% for either systolic or diastolic blood pressure within sleep or wake periods. RESULTS: One thousand five hundred seventy-seven ambulatory blood pressure monitoring studies from 701 CKiD participants were reviewed. Nighttime, daytime, and both types of hypertension were 19%, 7%, and 33%, respectively. Participants with both daytime and nocturnal hypertension had the highest risk of kidney replacement therapy. Among children with CKD, compared with those who were normotensive, those with isolated nocturnal hypertension had a hazard ratio of 1.49 ([CI, 0.97-2.28]; P=0.068) while those with both daytime and nocturnal hypertension had a HR of 2.23 ([CI, 1.60-3.11]; P<0.001) when adjusted for age, race, sex, and baseline proteinuria and glomerular filtration. Estimates for risk were similar among glomerular and nonglomerular participants but not significant in glomerular due to smaller sample size. CONCLUSIONS: The presence of both daytime and nocturnal hypertension is significantly associated with risk of kidney replacement therapy. Our study confirms the utility of ambulatory blood pressure monitoring in children with CKD. Identifying and controlling both daytime and nocturnal hypertension using ambulatory blood pressure monitoring may improve outcomes and delay CKD progression in this population.
BACKGROUND: Nocturnal hypertension is a risk factor for chronic kidney disease (CKD) progression among adults. In children, effects of nocturnal hypertension on CKD progression is less studied. METHODS: We investigated the relationships between nocturnal, daytime, or sustained hypertension and progression to kidney replacement therapy in children using Cox proportional hazards models. Nocturnal and diurnal hypertension respectively defined as: mean blood pressure >95th percentile and/or load >25% for either systolic or diastolic blood pressure within sleep or wake periods. RESULTS: One thousand five hundred seventy-seven ambulatory blood pressure monitoring studies from 701 CKiD participants were reviewed. Nighttime, daytime, and both types of hypertension were 19%, 7%, and 33%, respectively. Participants with both daytime and nocturnal hypertension had the highest risk of kidney replacement therapy. Among children with CKD, compared with those who were normotensive, those with isolated nocturnal hypertension had a hazard ratio of 1.49 ([CI, 0.97-2.28]; P=0.068) while those with both daytime and nocturnal hypertension had a HR of 2.23 ([CI, 1.60-3.11]; P<0.001) when adjusted for age, race, sex, and baseline proteinuria and glomerular filtration. Estimates for risk were similar among glomerular and nonglomerular participants but not significant in glomerular due to smaller sample size. CONCLUSIONS: The presence of both daytime and nocturnal hypertension is significantly associated with risk of kidney replacement therapy. Our study confirms the utility of ambulatory blood pressure monitoring in children with CKD. Identifying and controlling both daytime and nocturnal hypertension using ambulatory blood pressure monitoring may improve outcomes and delay CKD progression in this population.
Authors: Roberto Minutolo; Rajiv Agarwal; Silvio Borrelli; Paolo Chiodini; Vincenzo Bellizzi; Felice Nappi; Bruno Cianciaruso; Pasquale Zamboli; Giuseppe Conte; Francis B Gabbai; Luca De Nicola Journal: Arch Intern Med Date: 2011-06-27
Authors: Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina Journal: Pediatrics Date: 2017-08-21 Impact factor: 7.124
Authors: George C Roush; Robert H Fagard; Gil F Salles; Sante D Pierdomenico; Gianpaolo Reboldi; Paolo Verdecchia; Kazuo Eguchi; Kazuomi Kario; Satoshi Hoshide; Jorge Polonia; Alejandro de la Sierra; Ramon C Hermida; Eamon Dolan; Hernan Zamalloa Journal: J Hypertens Date: 2014-12 Impact factor: 4.844
Authors: Christine Y Bakhoum; Ronit Katz; Joshua A Samuels; Tala Al-Rousan; Susan L Furth; Joachim H Ix; Pranav S Garimella Journal: Clin J Am Soc Nephrol Date: 2021-11-12 Impact factor: 8.237
Authors: J C Peterson; S Adler; J M Burkart; T Greene; L A Hebert; L G Hunsicker; A J King; S Klahr; S G Massry; J L Seifter Journal: Ann Intern Med Date: 1995-11-15 Impact factor: 25.391
Authors: Mark Mitsnefes; Joseph Flynn; Silvia Cohn; Joshua Samuels; Tom Blydt-Hansen; Jeffrey Saland; Thomas Kimball; Susan Furth; Bradley Warady Journal: J Am Soc Nephrol Date: 2009-11-16 Impact factor: 10.121